<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00312091</url>
  </required_header>
  <id_info>
    <org_study_id>P1056</org_study_id>
    <secondary_id>10139</secondary_id>
    <secondary_id>PACTG P1056</secondary_id>
    <secondary_id>IMPAACT P1056</secondary_id>
    <nct_id>NCT00312091</nct_id>
  </id_info>
  <brief_title>Drug Levels of Tablet and Liquid Forms of Lamivudine, Nevirapine, and Stavudine in HIV Infected Thai Children</brief_title>
  <official_title>A Phase I/II Comparative Pharmacokinetic Study of the Fixed-Dose Combination (FDC) of Stavudine (d4T), Lamivudine (3TC), and Nevirapine (NVP) as GPO-VIR Pediatric Chewable Tablets Versus the Individual Liquid Formulations in HIV Infected Children 6 Months and Older to Less Than 13 Years of Age in Thailand</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the blood levels, absorption, and breakdown of&#xD;
      lamivudine (3TC), nevirapine (NVP), and stavudine (d4T) in a fixed-dose tablet to that of the&#xD;
      individual liquid formulations of the same anti-HIV drugs in HIV infected Thai children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Thai Ministry of Public Health strives to provide the HIV infected people of Thailand&#xD;
      with affordable antiretrovirals (ARVs). A fixed-dose combination tablet of 3TC, NVP, and d4T&#xD;
      is recommended as first-line treatment in HIV infected adults in Thailand. There has been no&#xD;
      similar product developed for children for several reasons: pediatric dosing is based on age,&#xD;
      weight, or body surface area; developmental changes may influence the bioavailability and&#xD;
      pharmacokinetics (PK) of ARVs; and medication adherence may also be a problem. The purpose of&#xD;
      this study is to gather bioavailability and PK data in children taking a fixed-dose tablet of&#xD;
      3TC, NVP, and d4T. This information will then be compared to the bioavailability and PK of&#xD;
      the individual liquid formulations of these ARVs.&#xD;
&#xD;
      This study has two stages. Stage 1 will last a minimum of 4 weeks; Stage 2 will last a&#xD;
      minimum of 8 weeks. In Stage 1, patients will be randomly assigned to one of two arms. Arm A&#xD;
      will receive the fixed-dose tablet twice daily for 2 weeks, then switch to the individual&#xD;
      liquid formulations twice daily for 2 weeks. Arm B will receive the individual liquid&#xD;
      formulations twice daily for 2 weeks, then switch to the fixed-dose tablet twice daily for 2&#xD;
      weeks. To encourage medication adherence, study staff will make home visits and phone calls&#xD;
      to each patient's parent or guardian the first week of each treatment regimen. Medical&#xD;
      history, a physical exam, and urine collection will occur on Days 11 and 25. Also on Days 11&#xD;
      and 25, patients will be admitted to the hospital to ensure 100% medication adherence and to&#xD;
      provide blood for PK studies.&#xD;
&#xD;
      Stage 1 patients are not eligible for Stage 2. In Stage 2, patients will be stratified by&#xD;
      body weight, then randomly assigned to one of two arms. Arm A will receive the fixed-dose&#xD;
      tablet twice daily for 4 weeks, then switch to the individual liquid formulations twice daily&#xD;
      for 4 weeks. Arm B will receive the individual liquid formulations twice daily for 4 weeks,&#xD;
      then switch to the fixed-dose tablet twice daily for 4 weeks. To encourage medication&#xD;
      adherence, study staff will make home visits and phone calls to each patient's parent or&#xD;
      guardian the first week of each treatment regimen. Medical history, documentation of direct&#xD;
      observation of therapy (DOT), a physical exam, and urine collection will occur on Days 25 and&#xD;
      53. Also on Days 25 and 53, patients will be admitted to the hospital to ensure 100%&#xD;
      medication adherence and to provide blood for PK studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparative bioavailability</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>therapeutic adequacy</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug absorption from standard pharmacokinetic (PK) analyses</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A, Stage 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet containing d4T, 3TC, and NVP taken orally twice daily for the first 4 weeks, then liquid formulations of d4T, 3TC, and NVP taken orally twice daily for the final 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A, Stage 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet containing d4T, 3TC, and NVP taken orally twice daily for 4 weeks, then liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B, Stage 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 2 weeks, then tablet containing d4T, 3TC, and NVP taken orally twice daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B, Stage 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 4 weeks, then tablet containing d4T, 3TC, and NVP taken orally twice daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine, nevirapine, and stavudine fixed-dose tablet</intervention_name>
    <description>7 mg d4T, 30 mg 3TC, 50 mg NVP tablet</description>
    <arm_group_label>A, Stage 1</arm_group_label>
    <arm_group_label>A, Stage 2</arm_group_label>
    <arm_group_label>B, Stage 1</arm_group_label>
    <arm_group_label>B, Stage 2</arm_group_label>
    <other_name>GPO-Vir</other_name>
    <other_name>d4T/3TC/NVP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Dosage dependent on weight. More information on this criterion can be found in the protocol.</description>
    <arm_group_label>A, Stage 1</arm_group_label>
    <arm_group_label>A, Stage 2</arm_group_label>
    <arm_group_label>B, Stage 1</arm_group_label>
    <arm_group_label>B, Stage 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <description>Dosage dependent on weight. More information on this criterion can be found in the protocol.</description>
    <arm_group_label>A, Stage 1</arm_group_label>
    <arm_group_label>A, Stage 2</arm_group_label>
    <arm_group_label>B, Stage 1</arm_group_label>
    <arm_group_label>B, Stage 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stavudine</intervention_name>
    <description>Dosage dependent on weight. More information on this criterion can be found in the protocol.</description>
    <arm_group_label>A, Stage 1</arm_group_label>
    <arm_group_label>A, Stage 2</arm_group_label>
    <arm_group_label>B, Stage 1</arm_group_label>
    <arm_group_label>B, Stage 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Stages 1 and 2:&#xD;
&#xD;
          -  HIV infected&#xD;
&#xD;
          -  On a highly active antiretroviral regimen (HAART) including NVP and 2 nucleoside&#xD;
             reverse transcriptase inhibitors and receiving a maintenance of NVP for at least 4&#xD;
             weeks prior to study entry and taking the current recommended oral dose every 12 hours&#xD;
&#xD;
          -  Willing to swallow or chew study drugs&#xD;
&#xD;
          -  Willing to be hospitalized for the 12 hour PK studies&#xD;
&#xD;
          -  Willing to use acceptable forms of contraception&#xD;
&#xD;
          -  Parent or guardian willing to provide informed consent&#xD;
&#xD;
        Inclusion Criteria for Stage 1:&#xD;
&#xD;
          -  Between 12 to 30 kg (26.5 to 66.1 lbs)&#xD;
&#xD;
        Inclusion Criteria for Stage 2:&#xD;
&#xD;
          -  Between 6 to 30 kg (13.2 to 66.1 lbs)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Certain abnormal laboratory values&#xD;
&#xD;
          -  Require certain medications&#xD;
&#xD;
          -  Grade 2 or greater vomiting within 30 days prior to study entry&#xD;
&#xD;
          -  Grade 2 or greater diarrhea within 30 days prior to study entry&#xD;
&#xD;
          -  History of immunological failure (CD4 percentage decrease of more than 30% within a&#xD;
             6-month period for children 6 years or younger OR CD4 cell count decrease of more than&#xD;
             30% within a 6-month period for children older than 6 years)&#xD;
&#xD;
          -  Current treatment for acute serious bacterial, viral, or opportunistic infection&#xD;
&#xD;
          -  History of dose-limiting toxicity requiring treatment discontinuation of any of the&#xD;
             study drugs&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs&#xD;
&#xD;
          -  Current surgical or medical problem affecting gastrointestinal motility or absorption&#xD;
             (e.g., ileus, ulcerative colitis) or liver function&#xD;
&#xD;
          -  Treatment with immune modulators or myelosuppressive, neurotoxic, pancreatotoxic,&#xD;
             hepatotoxic, or cytotoxic drugs within 30 days prior to study entry. Patients who have&#xD;
             received therapeutic vaccines are not excluded.&#xD;
&#xD;
          -  Treatment with experimental drugs within 30 days of study entry&#xD;
&#xD;
          -  Acute inflammation of the liver&#xD;
&#xD;
          -  Chemotherapy for active cancer&#xD;
&#xD;
          -  Any clinically significant diseases other than HIV infection or clinically significant&#xD;
             findings that, in the investigator's opinion, may interfere with the study&#xD;
&#xD;
          -  Inability to provide a reliable means of contact (e.g., telephone number)&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nirun Vanprapar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pediatric Infectious Unit, Department of Pediatrics, Siriraj Hopstial, Mahidol University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Sirikit National Institute of Child Health, Pediatric Infectious Unit</name>
      <address>
        <city>Bangkok</city>
        <state>Ratchathewi</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital Mahidol University CRS</name>
      <address>
        <city>Bangkok</city>
        <state>Ratchathewi</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Mai University Pediatrics-Obstetrics CRS</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonburi Hosp. CRS</name>
      <address>
        <city>Chonburri</city>
        <zip>20000 TH</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://aidsinfo.nih.gov/clinicaltrials/htmltrials_sp.asp?an=1590</url>
    <description>Haga clic aquí para ver información sobre este ensayo clínico en español.</description>
  </link>
  <reference>
    <citation>Chokephaibulkit K, Plipat N, Cressey TR, Frederix K, Phongsamart W, Capparelli E, Kolladarungkri T, Vanprapar N. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. AIDS. 2005 Sep 23;19(14):1495-9.</citation>
    <PMID>16135903</PMID>
  </reference>
  <reference>
    <citation>Hoody DW, Fletcher CV. Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children. Semin Pediatr Infect Dis. 2003 Oct;14(4):286-94. Review.</citation>
    <PMID>14724793</PMID>
  </reference>
  <reference>
    <citation>King JR, Kimberlin DW, Aldrovandi GM, Acosta EP. Antiretroviral pharmacokinetics in the paediatric population: a review. Clin Pharmacokinet. 2002;41(14):1115-33. Review.</citation>
    <PMID>12405863</PMID>
  </reference>
  <results_reference>
    <citation>Vanprapar N, Cressey TR, Chokephaibulkit K, Muresan P, Plipat N, Sirisanthana V, Prasitsuebsai W, Hongsiriwan S, Chotpitayasunondh T, Eksaengsri A, Toye M, Smith ME, McIntosh K, Capparelli E, Yogev R; IMPAACT P1056 Team. A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand. Pediatr Infect Dis J. 2010 Oct;29(10):940-4. doi: 10.1097/INF.0b013e3181e2189d.</citation>
    <PMID>20453709</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 5, 2006</study_first_submitted>
  <study_first_submitted_qc>April 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2006</study_first_posted>
  <disposition_first_submitted>September 1, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 1, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 26, 2009</disposition_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Stavudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

